Corium to Participate in BioPharma Dealmakers Webcast on New Innovations in Drug Delivery Technology
March 22 2017 - 7:30AM
Corium International, Inc. (Nasdaq:CORI), a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty transdermal products, today
announced that Joseph J. Sarret, M.D., Chief Business Officer, will
participate in a BioPharma Dealmakers webcast featuring five
companies innovating drug delivery technology. The webcast, part of
the BioPharma Dealmakers series of The Nature Publishing Group, is
scheduled for 11:00 am EDT/8:00 am PDT on March 29th.
This webcast will highlight a range of diverse technologies and
explain their applications in diseases such as oncology, CNS
diseases and women’s health. Technologies covered within the
webcast will include digitally controlled needle-free devices,
sustained and controlled transdermal delivery technology,
fiber-based technology for implantable devices, targeted
penetration matrix technology for non-invasive delivery and
location-specific nano machines for chemotherapy payload
delivery.
The webcast will conclude with a live roundtable discussion and
a Q&A section to allow the audience to ask questions
directly.
Corium has a strong track record of developing complex
transdermal products for partners and manufacturing them for
clinical development and commercial sale. The company is now
leveraging that expertise to build a high-value proprietary CNS
pipeline, initially focused on Alzheimer’s disease, which can
provide important benefits to patients and their families.
Dr. Sarret brings extensive US and international strategic
business development and corporate transaction experience in the
life science industry. Earlier in his career, he worked as a
practicing clinician focused on patients with human
immunodeficiency virus and as an attorney specializing in IP
transactional work.
Joining Dr. Sarret on the webcast will be Dr. Patrick Anquetil,
Chief Executive Officer of Portal Instruments Inc.; Dr. Kevin
Nelson, Founder & Chief Scientific Officer of TissueGen Inc.;
Dr. Paul Gavin, Chief Scientific Officer of Phosphagenics Limited;
and Dr. Roy Farfara, Chief Scientific Officer of TrioxNano. The
webcast will be moderated by Raveena Bhambra, Editor of BioPharma
Dealmakers. Ms. Bhambra has worked in the biopharma industry for
over 10 years specifically in the areas of dealmaking, partnering
and licensing.
For more information and to register for the webcast, please
access the BioPharma Dealmakers Webcast link here or by visiting
the Investors section of Corium’s website at
http://ir.coriumgroup.com/events.cfm. The webcast will be archived
on the Corium website for two weeks following the presentation.
About the BioPharma Dealmakers Webcast
BioPharma Dealmakers webcasts are dedicated to small and large
companies looking for commercial partnerships. Read the
quarterly BioPharma Dealmakers supplement in Nature Biotechnology
and Nature Reviews Drug Discovery.
About Corium
Corium International, Inc. is a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty pharmaceutical products that
leverage the company's broad experience with advanced transdermal
and transmucosal delivery systems. Corium has multiple proprietary
programs in preclinical and clinical development, focusing
primarily on the treatment of neurological disorders, with lead
programs in Alzheimer's disease. Corium has developed and is the
sole commercial manufacturer of seven prescription drug and
consumer products with partners Mayne Pharma and Procter &
Gamble. The company has two proprietary transdermal platforms:
Corplex™ for small molecules and MicroCor®, a biodegradable
microstructure technology for small molecules and biologics,
including vaccines, peptides and proteins. The company's late-stage
pipeline includes a contraceptive patch co-developed with Agile
Therapeutics and additional transdermal products that are being
developed with other partners. For further information, please
visit www.coriumgroup.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation
Reform Act of 1995, including statements regarding our clinical
trial and regulatory timing and plans, the achievement of clinical
and commercial milestones, and the advancement of our technologies
and our products and product candidates. Forward-looking statements
are based on management's current expectations and projections and
are subject to risks and uncertainties, which may cause Corium's
actual results to differ materially from the statements contained
herein. Further information on potential risk factors that
could affect Corium's business and its results are detailed in
Corium's Quarterly Report on Form 10-Q for the quarter
ended December 31, 2016, filed with the Securities and
Exchange Commission on February 14, 2017, and other reports as
filed from time to time with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, especially guidance on future financial or operating
performance, which speaks only as of the date they are made. Corium
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date they were made or to reflect the occurrence of
unanticipated events.
Corplex™ and MicroCor® are trademarks of Corium International,
Inc.
Source: Corium
Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
susan@smpcommunications.com
(201) 923-2049
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Apr 2024 to May 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From May 2023 to May 2024